Is FDA Bipolar or Complicit in Legitimizing Illegal Marketing?

The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent. Continue reading →

Marketing Trumps Safety: the case of Antipsychotics

"The story’s pretty clear, and pretty embarrassing for the profession of psychiatry, which has allowed itself to be led by marketing," says Dr. Robert Rosenheck, Yale. Continue reading →